Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RATIONAL-PT Dose-Ig: low-dose versus standard-dose IVIg in hematological malignancy
ACTRN12624000962538Phase 3Recruiting
- Sponsor
- Monash University
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of immune globulin in hypogammaglobulinemia and hematopoietic malignancies (2 arms), sponsored by Monash University. Primary endpoint: Event-free survival. Started Apr 2025; status: recruiting.
02
Drugs
immune globulin
03
Conditions
hypogammaglobulinemiahematopoietic malignancies
Beyond the preview
Go deeper on ACTRN12624000962538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000962538.